Ilia I. Ouspenski

Array ( [id] => 11588519 [patent_doc_number] => 20170112929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/174213 [patent_app_country] => US [patent_app_date] => 2016-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 97082 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17178391 [patent_doc_number] => 11155626 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Anti-human PD-L1 humanized monoclonal antibody and application thereof [patent_app_type] => utility [patent_app_number] => 16/084710 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 8341 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 261 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11304830 [patent_doc_number] => 09512216 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-06 [patent_title] => 'Use of TNFα inhibitor' [patent_app_type] => utility [patent_app_number] => 15/173191 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 23897 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15173191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350249 [patent_doc_number] => 20160368989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/166305 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 46483 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15166305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060790 [patent_doc_number] => 20160257752 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES' [patent_app_type] => utility [patent_app_number] => 15/167125 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 41392 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15167125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12813316 [patent_doc_number] => 20180162942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => TREATMENT OF RENAL CELL CARCINOMA [patent_app_type] => utility [patent_app_number] => 15/577661 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -84 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067702 [patent_doc_number] => 20160264666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'Antibodies Directed Against ICOS and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/165152 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 17520 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15165152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311739 [patent_doc_number] => 20160347849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'ANTIBODIES AGAINST OX40 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/166114 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 88 [patent_figures_cnt] => 88 [patent_no_of_words] => 102335 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15166114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060791 [patent_doc_number] => 20160257753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'HUMAN CTLA-4 ANTIBODIES AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/163332 [patent_app_country] => US [patent_app_date] => 2016-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 41324 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15163332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13289249 [patent_doc_number] => 10155800 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-18 [patent_title] => CTLA4-Ig immunoadhesins [patent_app_type] => utility [patent_app_number] => 15/159667 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 24474 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15159667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11270567 [patent_doc_number] => 20160333114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/156159 [patent_app_country] => US [patent_app_date] => 2016-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 42711 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15156159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410345 [patent_doc_number] => 20180256715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => ANTI-CTLA-4 BLOCKADE [patent_app_type] => utility [patent_app_number] => 15/571174 [patent_app_country] => US [patent_app_date] => 2016-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11122044 [patent_doc_number] => 20160319019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'Anti-PD-1 Antibodies' [patent_app_type] => utility [patent_app_number] => 15/152192 [patent_app_country] => US [patent_app_date] => 2016-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 20133 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15152192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11047566 [patent_doc_number] => 20160244524 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'Combination Immunotherapy for the Treatment of Cancer' [patent_app_type] => utility [patent_app_number] => 15/145780 [patent_app_country] => US [patent_app_date] => 2016-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 11188 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15145780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067712 [patent_doc_number] => 20160264675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD' [patent_app_type] => utility [patent_app_number] => 15/142538 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 93998 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15142538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763557 [patent_doc_number] => 10174113 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody [patent_app_type] => utility [patent_app_number] => 15/141769 [patent_app_country] => US [patent_app_date] => 2016-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 18730 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15141769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12205845 [patent_doc_number] => 20180051070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'Novel VISTA-Ig constructs and the use of VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders' [patent_app_type] => utility [patent_app_number] => 15/131691 [patent_app_country] => US [patent_app_date] => 2016-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 75 [patent_figures_cnt] => 75 [patent_no_of_words] => 104942 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15131691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107637 [patent_doc_number] => 20160304607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/130513 [patent_app_country] => US [patent_app_date] => 2016-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 42691 [patent_no_of_claims] => 103 [patent_no_of_ind_claims] => 56 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15130513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11449212 [patent_doc_number] => 09572837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-21 [patent_title] => 'Reducing immune tolerance induced by PD-L1' [patent_app_type] => utility [patent_app_number] => 15/093643 [patent_app_country] => US [patent_app_date] => 2016-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14410 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15093643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11009766 [patent_doc_number] => 20160206719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY' [patent_app_type] => utility [patent_app_number] => 15/091060 [patent_app_country] => US [patent_app_date] => 2016-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 37094 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15091060 [rel_patent_id] =>[rel_patent_doc_number] =>)